ONCOHealthcare · BiotechnologyONCO Stock Forecast: Onconetix, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 16 of 100 as at 1 Aug 2026 — in the weakest quartile.
ONCO stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Onconetix, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (98): Smaller than most of the companies we track.
Value (1): The shares cost a lot relative to the profits and assets behind them.
The rank is the raw material. Whether the rules would actually own Onconetix, Inc. — and when they’d sell — is the membership.
ONCO stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ONCO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Sept 2023 | Maxim Group | Downgrade | Hold | — |
| 26 Apr 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 1 Feb 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 Dec 2022 | HC Wainwright & Co. | Initiates | Buy | — |
| 8 Dec 2022 | Maxim Group | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ONCO analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Onconetix, Inc. (ONCO) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 0.0×
- Price / sales
- 4.2×
- Price / book
- 0.0×
- EV / EBITDA
- 0.4×
Cheaper than 75% of US stocks
Cheaper than 30% of US stocks
Cheaper than 92% of US stocks
Cheaper than 60% of US stocks
- Revenue growth (YoY)
- −78.9%
- Earnings growth (YoY)
- −78.9%
- Gross margin
- −7.7%
- Operating margin
- −9748.8%
- Net margin
- 77.6%
Higher than 3% of US stocks
Higher than 5% of US stocks
Higher than 4% of US stocks
Higher than 2% of US stocks
Higher than 98% of US stocks
- Return on equity
- −123.3%
- Return on assets
- −25.2%
- Dividend yield
- —
Higher than 11% of US stocks
Higher than 16% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
ONCO vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ONCO appears on the weeks it earns a place.
Frequently asked questions about ONCO stock
How does Ticker Nerd's model rank ONCO?
As at 1 Aug 2026, Onconetix, Inc. ranks 16 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).
What is the ONCO stock forecast for 2030?
No analyst covering Onconetix, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ONCO are extrapolating price history, which says nothing about the business.
How has ONCO stock performed over the past year?
Onconetix, Inc. returned -99.5% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Onconetix, Inc. do?
Onconetix Inc. is a commercial stage biotechnology company focused on the research, development, and commercialization of proprietary therapeutics, diagnostics, and services for oncology and men's health.
About Onconetix, Inc.
Onconetix Inc. is a commercial stage biotechnology company focused on the research, development, and commercialization of proprietary therapeutics, diagnostics, and services for oncology and men's health. It offers Entadfi, an FDA-approved once-daily oral pill combining finasteride and tadalafil for treating benign prostatic hyperplasia, a common prostate disorder. The company also provides Proclarix, an advanced in vitro protein-based blood diagnostic test designed for screening and diagnosing prostate cancer in men with indeterminate Prostate Specific Antigen levels. These products serve clinicians and patients by addressing key needs in prostate health and oncology, including treatment and early detection. Onconetix Inc. pursues partnerships, such as with LabCorp for Proclarix commercialization, to expand access in the United States, European Union, and other markets. Founded in 2018 and headquartered in Cincinnati, Ohio, Onconetix Inc. plays a role in advancing targeted solutions within the biotechnology sector.
CEO Ms. Karina M. Fedasz · 2 employees · United States · https://www.onconetix.com